ReviewThe Journal of clinical endocrinology and metabolism2021
Update on Novel Hormonal and Nonhormonal Male Contraceptive Development.
Review in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE).Journal of endocrinological investigation · 2022Guideline
- A Scalable Flow Cytometry Assay to Evaluate CatSper-mediated CaAndrology · 2026Article
- Structural Basis for BD1-Preferring 2,4-Disubstituted Pyrimidine BRDT Inhibitors.Journal of medicinal chemistry · 2026Article
- Reviewing the Implication of Aldehyde Dehydrogenases in Male Reproduction: Prospects for New Therapeutic Approaches.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Review
- Interest in new methods of "male contraception" in survey of people with a prior vasectomy in the United States.Contraception and reproductive medicine · 2025Article
- Clinician's guide to the management of azoospermia induced by exogenous testosterone or anabolic-androgenic steroids.Asian journal of andrology · 2025Review
- Development of a transdermal gel for reversible male contraception.Contraception · 2025Review
- Male Hormonal Contraception-Current Stage of Knowledge.Journal of clinical medicine · 2025Review
- Non-hormonal Contraception: Current and Emerging Targets.Advances in experimental medicine and biology · 2025Review
- Hydrogels in the clinic: An update.Bioengineering & translational medicine · 2024Review
- Contraceptive Care in the Rheumatic Diseases: A Review.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2024Review
- Article
- On-demand male contraceptives: gazing at the long road ahead.International journal of impotence research · 2024Article
- Hormone Regulation in Testicular Development and Function.International journal of molecular sciences · 2024Review
- Reversible Contraception in Males: An Obtainable Target?Biology · 2024Review
- Frequency, morbidity and equity - the case for increased research on male fertility.Nature reviews. Urology · 2024Review
- CaAnimal cells and systems · 2024Review
- GASZ self-interaction clusters mitochondria into the intermitochondrial cement for proper germ cell development.PNAS nexus · 2024Article
- Nonhormonal Male Contraceptive Development-Strategies for Progress.Pharmacological reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe advent of new methods of male contraception would increase contraceptive options for men and women and advance male contraceptive agency. Pharmaceutical R&D for male contraception has been dormant since the 1990s. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has supported a contraceptive development program since 1969 and supports most ongoing hormonal male contraceptive development. Nonhormonal methods are in earlier stages of development. CONTENT: Several hormonal male contraceptive agents have entered clinical trials. Novel single agent products being evaluated include dimethandrolone undecanoate, 11β-methyl-nortestosterone dodecylcarbonate, and 7α-methyl-19-nortestosterone. A contraceptive efficacy trial of Nestorone®/testosterone gel is underway. Potential nonhormonal methods are at preclinical stages of development. Many nonhormonal male contraceptive targets that affect sperm production, sperm function, or sperm transport have been identified. SUMMARY: NICHD supports development of reversible male contraceptive agents. Other organizations such as the World Health Organization, the Population Council, and the Male Contraception Initiative are pursuing male contraceptive development, but industry involvement remains limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.